Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: A randomized three-way crossover study

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue 8, 2006, Pages 1179-1187

  Thomson, A B R ^a   Cohen, P ^b   Ficheux, H ^b   Fiorentini, P ^b   Domagala, F ^b   Homerin, M ^b   Taccoen, A ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Negma GILD ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENATOPRAZOLE; PROTON PUMP INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG EFFECT; DRUG HALF LIFE; HELICOBACTER PYLORI; HUMAN; MALE; MEAL; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; STOMACH PH; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-ULCER AGENTS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; EATING; FASTING; GASTRIC ACIDITY DETERMINATION; GASTRIC JUICE; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; MALE; OMEPRAZOLE; PYRIDINES; STATISTICS, NONPARAMETRIC;

EID: 33646866368     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02781.x     Document Type: Article

References (28)

1. Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001 13 Suppl. 1 S29 33.
2. Physician's Desk Reference. Monographies of Proton Pump Inhibitors. Thomson Healthcare, Montvale, NJ, USA 2005.
3. Chiverton SG Howden CW Burget DW Hunt RH. Omeprazole (20 mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther 1992 6: 103 11.
4. Hatlebakk JG Katz PO Kuo B Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998 12: 1235 40.
5. Shimatani T Inoue M Kuriowa T Horikawa Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression. Aliment Pharmacol Ther 2004 19: 113 22.
6. Katz PO Hatlebakk JG Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. Aliment Pharmacol Ther 2000 14: 709 14.
7. Katz PO Castell DO Chen Y Andersson T Sostek MB. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther 2004 20: 399 406.
8. Peghini PL Katz PO Bracy NA Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998 93: 763 7.
9. Kuo B Catell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996 91: 1532 8.
10. Gillen D Wirz AA McColl KE. Esomeprazole 40 mg bd Produces Profound 24 h Acid Suppression with Minimal Acid Breakthrough. Proceedings of the AGA Annual Conference, Digestive Disease Week 2003, Orlando Florida, 17-22 May. Gastroenterology (Suppl.), April 2003 (Abstract S1610).
11. Hammer J Schmidt B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough. Aliment Pharmacol Ther 2004 19: 1105 10.
12. Katz PO Anderson C Khoury R Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998 12: 1231 4.
13. Uchiyama K Wakatsuki D Kakinoki B Takeuchi Y Araki T Morinaka Y. The long-lasting effect of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol 1999 51: 457 64.
14. Uchiyama K Wakatsuki D Kakinoki B Takeuchi Y Araki T Morinaka Y. Effects of TU-199, a novel H+, K+-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol 1999 24: 114 22.
15. Kakinoki B Ono C Yamazaki N Chikamatsu N Uchiyama K Morinaka Y. General pharmacological properties of the new proton pump inhibitor (±)-5- methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sylfinyl]-1H-imidazol[4, 5-b]pyridine. Methods Find Exp Clin Pharmacol 1999 21: 179 87.
16. Shin JM Cho YM Sachs G. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors. J Am Chem Soc 2004 126: 7800 11.
17. Domagala F Ficheux H. Pharmacokinetics of Tenatoprazole, a Novel Proton Pump Inhibitor, in Healthy Male Caucasian Volunteers. Proceedings of the AGA Annual Conference, Digestive Disease Week 2003, Orlando Florida, 17-22 May. Gastroenterology (Suppl.), April 2003 (Abstract #102823).
18. Galmiche JP Bruley des Varannes S Ducrotté P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life. Effects on intragastric pH and comparison with esomeprazole in Caucasian healthy volunteers. Aliment Pharmacol Ther 2004 19: 655 62.
19. Galmiche JP Sacher-Huvelin S Bruley des Varannes S, et al. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005 21 : 575 82.
20. Hunt RH Amstrong D James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005 100 : 1949 56.
21. Mock T Yatscoff R Foster R, et al. Clinical validation of the HellKit(TM): a 13C urea breath test used for the diagnosis of Helicobacter infection. Clin Biochem 1999 32 : 59 63.
22. Frazzoni M De Micheli E Savarino V. Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive reflux oesophagitis or non-erosive reflux disease. Aliment Pharmacol Ther 2003 18 : 1091 8.
23. Ours TM Fackler K Richter JE Vaezi MF. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003 98 : 545 50.
24. Nzeako UC Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002 16 : 1309 16.
25. Ouatu-Lascar R Fitzgerald RC Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999 117 : 327 35.
26. Lagergren J Bergström R Lindgren A Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. NEJM 1999 340 : 825 31.
27. Pehlivanov ND Olyaee M Sarosiek I McCallum RW. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther 2003 18 : 883 90.
28. Holloway RH Dent J Narielvala F Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996 38 : 649 54.